Hematologic Malignancies Clinical Trial
Official title:
BT13BTθ51 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha Beta T Cell and B Cell Depletion For Patients With Hematologic Malignancies
This is a single arm pilot study for patients with hematologic malignancies with alternative donor sources receiving unrelated or partially matched related/Haploidentical mobilized peripheral stem cells (PSCs) using the CliniMACS system for Alpha Beta T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and GVHD, and one year leukemia free survival.
The purpose of this research study is to evaluate a new method of T cell depletion using the Miltenyi CliniMACS™ device for patients undergoing a peripheral stem cell transplant utilizing either a unrelated donor or partially matched/haploidentical related donor. This new method is called α/β (alpha/beta) T cell depletion and CD19+ B cell depletion. This pilot study will evaluate if this new method of T cell and B cell depletion is a more effective way of removing T cells thus reducing the risk of severe acute and chronic GVHD and result in a durable engraftment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
| Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
| Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
| Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
| Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT01930981 -
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
|
N/A |